Digitizing Healthcare – Embracing change. Creating opportunity.

Emily Wyatt

The future of healthcare is digital

For many industries, embracing digitization has become a matter of survival. Healthcare has always had a reputation of being resistant to change, but consumer demand and a rapidly evolving technology-driven world have led the digitization of healthcare to move at a frantic pace.

In comparison with other industries, healthcare has been slow to take advantage of the digital revolution. Traditionally healthcare has always been a difficult industry in which to innovate; it is highly regulated, expensive, complex and risk averse. However, rising drug development costs, increased patient expectations, and a growing dependence on health resources, place the industry under increasing pressure to move with the times. Many organizations with an interest in health, including the pharmaceutical industry, medical technology companies, health insurers, and payers are focusing on the digital world. However, the strongest digital health innovators are now coming in from outside the industry.

How tech companies are driving digital transformation

Healthcare represents an incredibly lucrative opportunity for traditional technology companies. The tech giants – Alphabet (the parent company of Google), Amazon, Apple, Microsoft and IBM – are taking the lead and heavily investing their time, resource and talent into healthcare.

Each of the major tech companies are using their core business strengths to create digital health initiatives across a variety of platforms. These are being implemented at every touchpoint of the patient/health professional journey ranging from data storage, artificial intelligence (AI), e-commerce, voice-enabled solutions, consumer apps and wearables. By developing tools that patients and health professionals embrace, and through collaborations with healthcare providers, the Big 5 are poised to reinvent the healthcare industry.

Digitizing Healthcare White Paper from Deallus
DOWNLOAD WHITEPAPER

About the author

Emily Wyatt

Emily is a Senior Associate based in the London office. Since joining Deallus, Emily has lead research for top tier pharmaceutical clients supporting their global strategy to implement personalised healthcare initiatives across the value chain. She has also facilitated competitive simulation workshops looking at the impact of Tech disruption in healthcare. Emily has significant experience across a variety of therapeutic areas and industries including neuroscience, oncology, immune-oncology, companion diagnostics, liver diseases, autoimmune diseases and personalised healthcare.

Emily holds a MPhil in Bioscience Enterprise from the University of Cambridge and a BSc Honours in Biochemistry from the University of Bristol. Throughout her career, Emily has also developed strong expertise in the medical devices space, having led business development projects for medical device companies in oncology and inflammatory diseases.

You may also be interested in…

A message from our Chairwoman

At Deallus we are fortunate to have Ulrike Meier as our Chairwoman since 2020. Ulrike has written a brilliant blog reflecting on her time with Deallus so far and shares some insights into, even if removed from daily business, as Chairwoman, there is room to make a difference. From being authentic, focusing on the bigger picture, to providing motivation and guidance, Ulrike explores what key elements she prioritises in her role and how we can all play a part in organisation success.

World Immunization Week 2024

Decades of transformation, fueled by unprecedented innovation are continuously pushing the bar for what the vaccines industry needs to deliver. A tight balance of public and global health commitments, and commercial attractiveness.

Unlocking Insights at PharmaCI: A Recap from Deallus

At Deallus, we constantly strive to immerse ourselves in the latest developments and conversations within the competitive intelligence (CI) landscape. Recently, we had the privilege of attending PharmaCI in Munich, where we engaged in enriching discussions with esteemed clients, peers, and colleagues.

  • AI in pharma

Can AI really help you understand what matters in your market?

The impact of AI across our industry will be profound. It’s already driving faster identification of novel drug targets and drug discovery, better patient identification, accelerated drug development, earlier diagnosis, and more personalized healthcare.

To learn more about this topic, or to find out about ways in which Deallus can help you, please get in touch.

For any questions or comments on this thought piece, please reach out to Julie Munch Khan – Deallus Chief Commercial Officer

Julie Munch Khan – Deallus Chief Commercial Officer